Amsterdam, 19 - 20 March 2019

Schedule

Create your personal agenda –check the favourite icon

Mar 1908:55
Conference pass

Chair’s opening remarks

Keynotes
Navin Joshi, Global Head of Pricing & Access Capabilities, GlaxoSmithKline
Mar 1909:00
Conference pass

Overview of the rare diseases landscape and the challenges facing HTAs

Keynotes
Sheela Upadhyaya, Assoicate Director HST, National Institute for Health and Care Excellence
Mar 1909:20
Conference pass

How to capture and quantify patient value within a commercial strategy

Keynotes
Daniel Jackson, Global Head Of Market Access, Solutions And Strategy, UCB
Mar 1909:40
Conference pass

The Value of a Cure

Keynotes
Jane Erickson, Vice President, Covance Market Access and Phase IV Solutions, Covance Market Access
Mar 1910:00
Conference pass

What is going on in Quebec about Market Access?

Keynotes
  • Examining Quebec life sciences strategy: Integration of medicines and technological innovations
  • Achieving cost reduction and improving access to medicines
  • Re-editing the evaluation process for the introduction of innovative medication and technologies
Luc Boileau, Président-Directeur General, Inesss
Mar 1911:20
Conference pass

The admission of value in the new marketplace

Keynotes
Ryan Saadi, VP, Global Market Access, CSL Behring
Mar 1911:40
Conference pass

Biosimilars Pricing and access expectations in Europe

Keynotes
Mar 1912:00
Conference pass

25 Roundtables (max 15 PAX)

Keynotes
Roundtable 11: The use of registries to assess orphan drugs
Jan Span, Member Of The Cross-Committee Task Force On Registries And Senior Clinical Assessor, Medicines Evaluation Board The Netherlands
Roundtable 12: Making sustainable healthcare work
Michael Schroter, Partner, Viopas Partners
Roundtable 13: “Pricing Strategy – What to Do and When?”
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
Roundtable 14: Contract Innovation
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Roundtable 15: Price Negotiations with Payors in Ireland & the UK
Brenda Dooley, Founder & CEO, Axis Consulting
Roundtable 16: Phase III studies and HTA- or bringing HTA requirement in the development programs
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Roundtable 17: Working with Estonian Payers
Kart Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
Roundtable 18: Room At The Top? The Case For a Chief Value Officer and The Three Pillars of Responsibility: Value Communication, Value Creation and Value Governance
Roundtable 19: Shaping assets from inception to phase II to maximise pricing & market access potential
Adam Plich, Former Vice President, Head Of Pricing And Market Access Europe, Teva
Roundtable 1: Bridging the gap between clinical development and medical affairs, tailoring clinical trials to meet both MA and HTA requirements
Katerina Anokhina, Director, Medical Affairs, Uk And Ireland, Alexion Pharma UK
Soniya Mokashi, Global Senior Medical Affairs Physician, Norgine
Roundtable 20: Engaging with patients and improving outcomes
Dawn Ireland, President, CDH International
Roundtable 21: Exploring role of evidence in anti-infective value assessments
Keiko Tone, VP Global Market Access, Shionogi Inc
Roundtable 22: GDPR, Big Data, and Re-designing Consent in Health-related Research
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Roundtable 23: The SmPC: friend or foe in access and pricing?
Mauricio Alvarez Reyes, Market Access Expert, Independent
Roundtable 24: Exploring the landscape of drug pricing, spending and affordability in the U.S.
Robert Popovian, Vice President Of Government Relations, Pfizer
Roundtable 2: Examining emerging trends for market access in LMICs, opportunities and challenges
Hector Castro, Senior Technical Director- Pharmaceutical Economics & Financing, Management Science For Health
Roundtable 3: Capability building for RWE
Elena Panitti, Global Rwe Capability Building Lead, Novartis
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Angelina Irizari Policarpio, Head Of US HEOR Field Team and US Quality, Boehringer Ingelheim
Roundtable 4: Payer engagement in the world of orphan drugs
Fabrizio Zucca, Director Patient Access Dach, Sobi
Roundtable 7: Role of RWE in oncology
Roundtable 8: Exploring regulatory and market access developments in advanced therapies
Renske Ten Ham, Phd Candidate, Utrecht University
Roundtable 9: Accelerating access to treatments for rare diseases
Mar 1914:10
Conference pass
Mar 1914:10
Conference pass
Mar 1914:10
Conference pass
Mar 1914:10
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Alexander Natz, Secretary General, EUCOPE
Mar 1914:10
Conference pass

Chair’s remarks

HTA
Anjan Chatterjee, Global Head Of Real World Evidence, Boehringer Ingelheim Pharma GmbH & Co. KG
Mar 1914:10
Conference pass

Chair’s remarks

EMERGING MARKETS, SOUTH KOREA & JAPAN
Navin Joshi, Global Head of Pricing & Access Capabilities, GlaxoSmithKline
Mar 1914:10
Conference pass

Chair’s remarks

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1914:15
Conference pass

Presentation cancelled

EVIDENCE
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Mar 1914:15
Conference pass

Developments in indication and combination pricing models

PRICING & MARKET ACCESS
  • A look at the reimbursement and pricing environment and challenges for indication-based and combination therapy pricing
  • Addressing the information gap: Infrastructure needs
  • Where are we? Case studies on indication-based and combo pricing
Mar 1914:15
Conference pass

From drug access to Value Based Healthcare

RARE DISEASES
Lara Pippo, Head Of Market Access, C.S.L. Behring Spa
Mar 1914:15
Conference pass

HTA in the world of digital health.

BIG DATA, DIGITAL HEALTH & ANALYTICS
Mar 1914:15
Conference pass

Defining the value of oncology drugs: the regulatory, HTA and clinicians’ perspective

HTA
Irina Odnoletkova, VP Health Technology Assessment, Apogenix
Mar 1914:15
Conference pass

Emerging trends for market access in LMICs, opportunities and challenges

EMERGING MARKETS, SOUTH KOREA & JAPAN
Hector Castro, Senior Technical Director- Pharmaceutical Economics & Financing, Management Science For Health
Mar 1914:15
Conference pass

The Canadian perspective and experience on Biosimilars

BIOSIMILARS
Elena Lungu, Manager of Policy Development, PMPRB
Mar 1914:35
Conference pass

Biopharmaceutical Acceleration Model for product development and commercialization

EVIDENCE
David Thompson, Senior Vice President, Head of Thought Leadership, Real World And Late Phase Research, Syneos Health
Mar 1914:35
Conference pass

The Transaction Price Opportunity: A Guide to Maximize its Value

PRICING & MARKET ACCESS
Alejandra Garitonandía, X, Vistex
Mar 1914:35
Conference pass

Patient engagement in the world of rare diseases

RARE DISEASES
Ana Palma, Senior Director Global HTA & Patient Access Lead, Sobi
Mar 1914:35
Conference pass

Beyond data - Deriving Actionable Intelligence

BIG DATA, DIGITAL HEALTH & ANALYTICS
Simon Swift, Managing Director, Methods Analytics
Mar 1914:35
Conference pass

Breaking down the ‘Great Wall’: do the evolving market access policy dynamics in China represent the next big opportunity of Pharma?

EMERGING MARKETS, SOUTH KOREA & JAPAN
Amy Wang, Life Sciences Consultant, Navigant
Mar 1914:45
Conference pass

Increasing availability of biosimilars and examining market access policies

BIOSIMILARS
Sue Naeyaert, Vice-President Global Government Affairs, Policy and Pharmacoeconomics Biosimilars, Fresenius Kabi
Mar 1914:55
Conference pass

USA Perspective: FDA’s Framework for Evaluating RWD/ RWE for Use in Regulatory Decisions

EVIDENCE
Nneka Onwudiwe, Founder and Chief Executive Officer, Pharmacoeconomics Consultants of America
Mar 1914:55
Conference pass

The SmPC: friend or foe in access and pricing?

PRICING & MARKET ACCESS
Mauricio Alvarez Reyes, Market Access Expert, Independent
Mar 1914:55
Conference pass

Redesigning pricing for the era of orphan drugs

RARE DISEASES
Herve Lilliu, CEO, inbeeo
Mar 1914:55
Conference pass

The use of Ehealth tools to measure health outcomes for pricing purposes

BIG DATA, DIGITAL HEALTH & ANALYTICS
Geert Pelsmaeker, General Manager, Leaphy
Mar 1914:55
Conference pass

European HTA - chances and risks. A German payer's view

HTA
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Mar 1914:55
Conference pass

How to expand access to wider populations in Low & Middle Income countries: the business impact of innovative thinking

EMERGING MARKETS, SOUTH KOREA & JAPAN
Mar 1915:15
Conference pass

Chair’s remarks

EVIDENCE
Angelina Irizari Policarpio, Head Of US HEOR Field Team and US Quality, Boehringer Ingelheim
Mar 1915:15
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Diane Munch, Head Of Global Pricing, Patient And Health Impact, Pfizer
Mar 1915:15
Conference pass

Chair’s remarks

RARE DISEASES
Axel Boehnke, Director Market Access (Global Responsibility), MorphoSys AG
Mar 1915:15
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Mar 1915:15
Conference pass
Mar 1915:15
Conference pass

Chair’s remarks

EMERGING MARKETS, SOUTH KOREA & JAPAN
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Mar 1915:15
Conference pass

Chair’s remarks

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1915:20
Conference pass

RWE – disrupter or quiet evolution?

EVIDENCE
Sandy Leonard, Vice President Of Medical Evidence And Observational Research, AstraZeneca
Mar 1915:20
Conference pass

Market access requirements in Germany

PRICING & MARKET ACCESS
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer Ingelheim Biopharmaceuticals Gmbh
Mar 1915:20
Conference pass

Using payer data to support rare disease treatments in Germany

RARE DISEASES
  • Reliability
  • Analyses
  • Outcome
Axel Boehnke, Director Market Access (Global Responsibility), MorphoSys AG
Mar 1915:20
Conference pass

Benefit assessment of orphan drugs in Germany

BIG DATA, DIGITAL HEALTH & ANALYTICS
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Mar 1915:20
Conference pass

Why investors care about value and affordability

VALUE
Michael Schroter, Partner, Viopas Partners
Mar 1915:20
Conference pass

The Sanofi Espoir Foundation- Providing new payment access systems to emerging markets

EMERGING MARKETS, SOUTH KOREA & JAPAN
Valerie Faillat, Head Of Sanofi Espoir Foundation, Sanofi
Mar 1915:20
Conference pass

How to fill in the gap: improving patient access to value-added medicines

BIOSIMILARS
Catarina Lopes Pereira, Market Access Manager, Medicines for Europe
Mar 1915:40
Conference pass

Spending trends for cancer. What does the evidence say?

EVIDENCE
Mar 1915:40
Conference pass

Early Integrated Scientific Advice: A Key to Optimal PRMA?

PRICING & MARKET ACCESS
Mar 1915:40
Conference pass

4D Insights - powering access

BIG DATA, DIGITAL HEALTH & ANALYTICS
  • Aligning Payers, Policy Markers, Prescribers and Patient Insight using the power of Big Data
  • Real-time Insights giving competitive advantage
  • Measuring impact in real-time from within the health system
David Williams, Chief Medical Officer, Visformatics
Mar 1915:40
Conference pass

Creating Value with Outcome Based Contracts: a case from the industry

VALUE
Sania Chouman, Global Market Access Lead, Takeda
Mar 1915:40
Conference pass

Insights into the new HTA roll out in Japan

EMERGING MARKETS, SOUTH KOREA & JAPAN
Taro Fujimoto, Policy & External Affairs Manager, Bayer Pharmaceuticals
Mar 1915:50
Conference pass

Rewarding Innovation in Drug Development

RARE DISEASES
Emily Saadi, Senior Undergraduate, Health Care Policy & Management, Georgetown University
Mar 1915:50
Conference pass

Delivering affordable and sustainable medicines to patients across Europe through Biosimilars

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1916:00
Conference pass

What patients expect from clinical research and researchers - and how patient advocacy can help deliver it

EVIDENCE
Richard Stephens, Chair Of Consumer Liaison Group, National Cancer Research Institute (NCRI)
Mar 1916:00
Conference pass

The pharmaceutical market of the Russian Federation: trends and prospects

PRICING & MARKET ACCESS
Anastasiya Stepanova, State Authorities Manager, JSC Nizhpharm
Ivan Glushkov, External Affairs Department Director, S.T.A.D.A.
Mar 1916:00
Conference pass

GDPR, Big Data, and Re-designing Consent in Health-related Research

BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Mar 1916:00
Conference pass

Measuring the value of improved workflow efficiency and safety of drug administration with prefilled syringes

VALUE
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, PS, B.D. Pharmaceuticals Systems
Mar 1916:00
Conference pass

Reimbursement and risk-sharing in South Korea

EMERGING MARKETS, SOUTH KOREA & JAPAN
Jeonghoon Ahn, Director, National Evidence-based Healthcare Collaborating Agency
Mar 1916:50
Conference pass

Chair’s remarks

EVIDENCE
Deven Chauhan, Senior Director, Value Evidence Leader, GlaxoSmithKline
Mar 1916:50
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Cristina Martin-Rinconada, Head of Value & Access for International Partners Markets (MENA & CEER Regions), Biogen
Mar 1916:50
Conference pass

Chair’s remarks

RARE DISEASES
Mar 1916:50
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Waldemar Ockert, Director, RWI Business Market Analytics, Astellas
Mar 1916:50
Conference pass

Chair’s remarks

EMERGING MARKETS, SOUTH KOREA & JAPAN
Camille Harfouche, Regional Office Lead, Algorithm
Mar 1916:50
Conference pass

Chair’s remarks

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1916:50
Conference pass

Chair’s remarks

REIMBURSEMENT
Igor Rudychev, Senior Director, Business Insights, AstraZeneca
Mar 1916:55
Conference pass

Use of value frameworks within oncology in Europe

EVIDENCE
  • Innovation and launches in oncology are moving at a rapid pace, potentially resulting in a delay in formal reimbursement appraisal and guidance
  • A number of value frameworks have been developed with the intent of providing rapid advice to oncologists on the clinical benefit of these new drugs
  • These value frameworks have many advantages, including clarity and brevity, but they do not replace the full value assessment of a formal HTA
Gwilym Thompson, Director Worldwide Heor, BMS
Mar 1916:55
Conference pass

Integrating care to secure early access and effective pricing

PRICING & MARKET ACCESS
Andrea Mantovani, Market Access Expert, Independent
Mar 1916:55
Conference pass

Utilising disease registries for orphan drug launch

RARE DISEASES
  • Utilising disease registries is vital in rare diseases and a multicountry, multi-stakeholder approach will be discussed
  • In Europe, linkage is needed as well between registries and EU Reference networks and this can prove to be an invaluable relation ship
  • Technological challenges are a problem and potential approaches will be explored
Peter Rutherford, Global Medical Lead Of Orphan Renal Diseases, Vifor Pharma Group
Mar 1916:55
Conference pass

Digital Therapeutics: The promise and the evidence

BIG DATA, DIGITAL HEALTH & ANALYTICS
Oliver Gassner, Head Digital Health Intelligence | Emea, Bayer
Mar 1916:55
Conference pass

Working with stakeholders to facilitate the entry of CAR-T in Europe

EMERGING MARKETS, SOUTH KOREA & JAPAN
Neil Mulcock, Vice President Government Affairs and Policy, Gilead Sciences
Mar 1916:55
Conference pass

The Belgian perspective and recent experiences in the regulatory biosimilar landscape

BIOSIMILARS
Mar 1916:55
Conference pass

Roadmap to Reimbursement: A Review of Successes and Stumbles

REIMBURSEMENT
Mar 1917:15
Conference pass

Using RWE across the life cycle

EVIDENCE
Anne Marciniak, Head of Market Access, Europe, Aimmune
Mar 1917:15
Conference pass

Review of International Reference Pricing

PRICING & MARKET ACCESS
Mar 1917:15
Conference pass

Marketing authorisation application for ultra orphan drugs

RARE DISEASES
Jan Span, Member Of The Cross-Committee Task Force On Registries And Senior Clinical Assessor, Medicines Evaluation Board The Netherlands
Mar 1917:15
Conference pass

Access environment and challenges in the Middle East and North Africa

EMERGING MARKETS, SOUTH KOREA & JAPAN
Camille Harfouche, Regional Office Lead, Algorithm
Mar 1917:15
Conference pass

Realising the insurance business model to establish effective partnership working

REIMBURSEMENT
Charles De Cidrac, Director Of Health Insurance, AXA
Mar 1917:25
Conference pass

Access to Medicines & Access to Health-related Research: Digital Health Literacy and a European Public Health Library

BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Mar 1917:25
Conference pass

Discussion: Summary of thoughts & Q/A

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Bart Vermeulen, Deputy Director Healthcare At Office Of The Minister Of Social Affairs And Public Health, Belgian Federal Government
Elena Lungu, Manager of Policy Development, PMPRB
Catarina Lopes Pereira, Market Access Manager, Medicines for Europe
Sue Naeyaert, Vice-President Global Government Affairs, Policy and Pharmacoeconomics Biosimilars, Fresenius Kabi
Mar 1917:35
Conference pass

Evidentry standards for RWE in a changing world

EVIDENCE
Chris L Pashos, Vice President Of Global Evidence Strategy, AbbVie
Mar 1917:35
Conference pass

Insights for NICE: The evolving landscape for market access

PRICING & MARKET ACCESS
Carla Deakin, Programme Director – Commercial & Managed Access, NICE
Mar 1917:35
Conference pass

Innovative Value based contracting for gene therapy

RARE DISEASES
Mar 1917:35
Conference pass

Emerging Market and Vaccines

EMERGING MARKETS, SOUTH KOREA & JAPAN
Alen Marijam, Heor Senior Manager, Em, GlaxoSmithKline
Mar 1917:35
Conference pass

Reimbursement within the world of Oncology

REIMBURSEMENT
  • Oncology Environment and Patient Access to the Oncology Therapies
  • Patient Access & Support Programs in Oncology
  • Reimbursement issues and impact of the reimbursement delays in Oncology
Igor Rudychev, Senior Director, Business Insights, AstraZeneca

Create your personal agenda –check the favourite icon

Mar 2009:00
Conference pass

Germany and the EU: current developments

Keynotes
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Federal Ministry of Health Germany
Mar 2009:20
Conference pass

Innovative Solutions for Fast-Track Approvals

Keynotes
Mar 2009:40
Conference pass

Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve access and pricing

Keynotes
  • Overview of key European and global initiatives and next steps
  • Looking at the role of technological innovation in access, pricing and evidence
  • Working with payers, patients and pharma to generate value
Gustavo Saraiva Dos Anjos, Head of Market Access, Respiratory Pipeline, GlaxoSmithKline
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
Jaume Vidal, Policy Advisor-Europe, Health Action International
Saira Jan, Director Of Pharmacy Strategy And Clinical Integration, Blue Cross Blue Shield of New Jersey
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Federal Ministry of Health Germany
Mar 2011:00
Conference pass

Roundtables

Keynotes
Nicki Catterick-Kang, Head of Pricing UK and Ireland, Merck Group
Adam Plich, Former Vice President, Head Of Pricing And Market Access Europe, Teva
Mark Macgregor, Co-Vice Chair, Scottish Medicines Consortium, Nhs Scotland
Anindita Sinha, Director, Global Market Access, Pfizer
Katja Rudell, Honorary Research Fellow, Queen Mary University of London
Mario Ouwens, Statistical Science Director, Astra Zeneca
Bart Van Den Daele, Head of External Affairs – Director Market Access, Gilead Sciences Belgium Bvba
Bertrand Tardivel, General Manager, Frehel GmbH
Josie Godfrey, Independent, Duchenne
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna
Matt Slabbert, Head Of Market Access, Advocacy And Policy, Anz, Bayer Pharmaceuticals
Tal Morginstin, Director, Nlhs (National List Of Health Services) Assessment Division, Ministry of Health
Melissa Paige, Uva Cancer Center, Oncology Patient Access Principal Coordinator, Patient Advocate, U.V.A. Health System
Anne Marciniak, Head of Market Access, Europe, Aimmune
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh
Jenny Ebert, National Account Director, Genzyme Sanofi Corp
Richard Stephens, Chair Of Consumer Liaison Group, National Cancer Research Institute (NCRI)
Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen
Mar 2012:00
Conference pass

Chair’s remarks

EVIDENCE
Gundula Schneidewind, Head Ethics & Compliance, Europe & Canada, Takeda
Mar 2012:00
Conference pass

Chair’s remarks

PRICING AND MARKET ACCESS
Elizabeth Mckenna, Head Of Market Access Uk And Ireland, Vertex Pharmaceuticals
Mar 2012:00
Conference pass

Chair’s remarks

RARE DISEASES
Josie Godfrey, Independent, Duchenne
Mar 2012:00
Conference pass
Mar 2012:00
Conference pass
Mar 2012:00
Conference pass

Chair’s remarks

MANAGED ENTRY AGREEMENTS
Giuseppe Rosano, Member Of The Cardiovascular Working Party, European Medicines Agency
Mar 2012:05
Conference pass

Federated & Harmonised Real World Research in the EU 2020+: A Convergence of Intent, Collaboration & Technology?

EVIDENCE
  • The next decade of RWD/RWE-based research in Europe – the federated model and edge analytics
  • Data harmonisation – an international initiative and the Rosetta Stone of RWD?
  • What have we learned from IMI EMIF, from its original inception, project experience, and sustainability scale up
  • The premise for EHDN, aims and likely impact
  • Meeting the needs of multiple stakeholders
Mar 2012:05
Conference pass

Learnings from the Netherlands in the world of pricing and market access

PRICING AND MARKET ACCESS
Jolanda Koenders, Head Of Pricing And Market Access Pharma, Novartis
Mar 2012:05
Conference pass

Value based medicine: whose values?

RARE DISEASES
Mark Macgregor, Co-Vice Chair, Scottish Medicines Consortium, Nhs Scotland
Mar 2012:05
Conference pass

Pharmaceutical Affordability

AFFORDABILITY
  • Ability to Pay versus Willingness to Pay
  • Considerations for Product-specific and Patient-specific affordability programs
  • Partnering with payers/policy makers
John Alter, Vice President Pricing And Market Access, Pfizer
Mar 2012:05
Conference pass

Developing advanced therapies for rare disease: is this sustainable?

ADVANCED THERAPIES
Diego Ardigo, Research And Development Rare Diseases Unit Head, Chiesi Farmaceutici SpA
Mar 2012:05
Conference pass

Latest developments in managed entry agreements for Europe

MANAGED ENTRY AGREEMENTS
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Mar 2012:25
Conference pass

EUnetHTA and Joint Assessments: Focus on the BeNeLuxA Collaboration

PRICING AND MARKET ACCESS
Rosemary Jose, Director, Strategic Market Access, Pharmerit International
Mar 2012:25
Conference pass

Update on MoCA

RARE DISEASES
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Mar 2012:25
Conference pass

Solving the affordability problem – partnering for improved value description is the following

AFFORDABILITY
Mar 2012:25
Conference pass

Health Economic Modelling in Gene Therapies

ADVANCED THERAPIES
Gene therapies raise new challenges when it comes to developing models for use in health technology assessment (HTA), burden of illness and value demonstration. Tried-and-true methods pose special issues, as applied to genetic interventions. This session is a discussion of potential approaches to modeling for gene therapies, and the advantages and disadvantages of various modeling approaches as applied to these interventions.
Ion Agirrezabal, Senior Consultant, Covance Market Access and Phase IV Solutions, Covance Market Access
Mar 2012:35
Conference pass

The role of evidence in anti-infective value assessments

EVIDENCE
Keiko Tone, VP Global Market Access, Shionogi Inc
Mar 2012:35
Conference pass

Implementation of managed entry agreements over the last decade in Australia

MANAGED ENTRY AGREEMENTS
Matt Slabbert, Head Of Market Access, Advocacy And Policy, Anz, Bayer Pharmaceuticals
Mar 2012:45
Conference pass

Understanding the US healthcare model: examining oncology treatments

PRICING AND MARKET ACCESS
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna
Mar 2012:45
Conference pass

Market access considerations for rare disease treatments

RARE DISEASES
Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen
Mar 2012:45
Conference pass

Achieving affordability in South America

AFFORDABILITY
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Mar 2012:45
Conference pass

Access considerations in the world advanced therapies

ADVANCED THERAPIES
  • CAR T-Cell Therapy, a new therapeutic approach: Between euphoria and scepticism
  • Drug or therapeutic method: first experiences in the German health care system
  • Most expensive cancer treatment ever: New approaches for affordability and sustainability
Bertrand Tardivel, General Manager, Frehel GmbH
Mar 2014:05
Conference pass

Chair’s remarks

EVIDENCE
Anne Marciniak, Head of Market Access, Europe, Aimmune
Mar 2014:05
Conference pass

Chair’s remarks

PRICING AND MARKET ACCESS
David Watson, Director Pricing And Reimbursement, ABPI
Mar 2014:05
Conference pass

Chair’s remarks

RARE DISEASES
Inge Bliestle, Chief Operating Officer, TolerogenixX
Mar 2014:05
Conference pass

Chair’s remarks

CONTRACTING AND PRICE TENDERING
Marcela Junqueira, Head Of Strategic Affairs And Health Economics, Janssen Pharmaceutical
Mar 2014:05
Conference pass
Mar 2014:05
Conference pass

Chair's remarks

PATIENT AND PAYER ENGAGEMENT
Ad Schuurman, Senior Advisor International Affairs, National Health Care Institute (ZIN), the Netherlands
Mar 2014:10
Conference pass

Precision medicine in oncology: challenges and possible solutions from a payer’s perspective

EVIDENCE
  • What are the key challenges we face in commissioning tests and treatments in this fast-paced and innovative field?
  • How can we ensure our patients have access to tests and treatments that are safe and effective despite limited evidence?
  • What solutions could be considered to manage costs to payers (and our customers) and safeguard precision medicine as a sustainable option in the future?
Lucy Hoppe, Clinical Effectiveness Manager (Evidence Synthesis) In The Clinical Effectiveness Team, Bupa
Mar 2014:10
Conference pass

Access in the new NHS landscape

PRICING AND MARKET ACCESS
Diar Fattah, Associate Director Of Medicines Optimisation, N.H.S._Dartford Gravesham and Swanley C.C.G.
Mar 2014:10
Conference pass

Launching rare disease products to a world market

RARE DISEASES
Mar 2014:10
Conference pass

Launch success and challenges in establishing the optimal price and contracting strategy

CONTRACTING AND PRICE TENDERING
Steve Sandor, Vice President, Market Access and Trade, Paratek Pharmaceuticals , Inc.
Mar 2014:10
Conference pass

Developments in CAR-T for Russia

ADVANCED THERAPIES
Daria Tolkacheva, Head Of Health Economics, JSC BIOCAD
Mar 2014:10
Conference pass

Engaging with patients and improving outcomes

PATIENT AND PAYER ENGAGEMENT
Dawn Ireland, President, CDH International
Mar 2014:30
Conference pass

Ensuring evidence generation plans support value: Influencing early stage development

EVIDENCE
Deven Chauhan, Senior Director, Value Evidence Leader, GlaxoSmithKline
Mar 2014:30
Conference pass

Quantifying the ‘patient voice’: the importance of tolerability and quality-of-survival in HTA decisions

PRICING AND MARKET ACCESS
  • HTA and payer-relevant quantitative concepts to characterize AE profiles and tolerability will be reviewed
  • HTA acceptance of these quant. approaches will be illustrated and appraised
  • Examples and (potential future) approaches, for HTA and Access success will be discussed
Reg Waldeck, Market Access Strategy Leader, Bayer Corp
Mar 2014:30
Conference pass

Clinical uncertainties management: can PBRSA fill the gap and optimize orphans’ market access?

RARE DISEASES
Entela Xoxi, Former Aifa, Universita Cattolica Del Sacro Cuore
Mar 2014:30
Conference pass

Risks in CAR-T commercialisation - understanding barriers to entry

ADVANCED THERAPIES
Mar 2014:30
Conference pass

Bridging payer and regulatory rules: How far are we?

PATIENT AND PAYER ENGAGEMENT
Ad Schuurman, Senior Advisor International Affairs, National Health Care Institute (ZIN), the Netherlands
Mar 2014:40
Conference pass

Contracting and price tendering for cancer treatments

CONTRACTING AND PRICE TENDERING
Marcela Junqueira, Head Of Strategic Affairs And Health Economics, Janssen Pharmaceutical
Mar 2014:50
Conference pass

Industry and payer collaboration: A Myriad Genetics Case Study

EVIDENCE
Laura O'Hanlon, Associate Director, International Market Access/Reimbursement, Myriad genetics
Mar 2014:50
Conference pass

Pursuing a successful market access strategy in the world of orphan drugs

RARE DISEASES
Mar 2014:50
Conference pass

Using evidence to support pricing for gene therapies

ADVANCED THERAPIES
Omar Dabbous, VP, Health Economics And Outcomes Research, AveXis Inc
Mar 2014:50
Conference pass

Evolving the payer partnership to foster greater innovation

PATIENT AND PAYER ENGAGEMENT
Dan Pettitt, VP Immunology Market Access and Policy Global Commercial Strategy Organization, Janssen Pharmaceuticals
Mar 2015:40
Conference pass
Mar 2015:40
Conference pass

Chair’s remarks

PRICING AND MARKET ACCESS
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Mar 2015:40
Conference pass

Chair’s remarks

RARE DISEASES
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Mar 2015:40
Conference pass

Chair’s remarks

MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
Mar 2015:40
Conference pass

Chair’s remarks

ADVANCED THERAPIES
Alexander Natz, Secretary General, EUCOPE
Mar 2015:40
Conference pass

Chair’s remarks

PATIENT AND PAYER ENGAGEMENT
Anindita Sinha, Director, Global Market Access, Pfizer
Mar 2015:45
Conference pass

Pay for performance: discussing the first large scale study into efficacy of the model

EVIDENCE
Mar 2015:45
Conference pass

Developments in pricing and patient access for speciality treatments

PRICING AND MARKET ACCESS
Diann Potestio, VP Market Access, Ascendis Pharma A/S
Mar 2015:45
Conference pass

Accelerating access to treatments for rare diseases

RARE DISEASES
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Mar 2015:45
Conference pass

Accounting profitability and the political process: the case of R&D accounting in the pharmaceutical industry

MEDICAL AND GOVERNMENTAL AFFAIRS
Mar 2015:45
Conference pass

Examining the regulatory landscape for CAR-T

ADVANCED THERAPIES
  • CAR T-Cell Therapy, a new therapeutic approach: Between euphoria and scepticism
  • Drug or therapeutic method: first experiences in the German health care system
  • Most expensive cancer treatment ever: New approaches for affordability and sustainability
Detlev Parow, Head Pharmaceutical Department, D.A.K.
Mar 2015:45
Conference pass

Best practices in the role of patient advocates in EUnetHTA Joint Assessments

PATIENT AND PAYER ENGAGEMENT
Rudy Dupree, Senior Project Manager, Zorginstituut
Mar 2016:05
Conference pass

The SIDE-L framework: when is an observational trial good enough to be used for labeling purposes

EVIDENCE
Mario Ouwens, Statistical Science Director, Astra Zeneca
Mar 2016:05
Conference pass

Ensuring a successful entry into the Danish hospital sector

PRICING AND MARKET ACCESS
Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark
Mar 2016:05
Conference pass

Medical drug management a US payer perspective

MEDICAL AND GOVERNMENTAL AFFAIRS
Saira Jan, Director Of Pharmacy Strategy And Clinical Integration, Blue Cross Blue Shield of New Jersey
Mar 2016:05
Conference pass

From AD to oncology – the role of the patient in reimbursement

PATIENT AND PAYER ENGAGEMENT
Anindita Sinha, Director, Global Market Access, Pfizer
Mar 2016:15
Conference pass

Solving the evidence crisis: patient driven collaborations

RARE DISEASES
Josie Godfrey, Independent, Duchenne
Mar 2016:15
Conference pass

Market access for ATMPs in Germany

ADVANCED THERAPIES
Alexander Natz, Secretary General, EUCOPE
Mar 2016:25
Conference pass

The role of RWE in HTAs and regulatory affairs in Germany

EVIDENCE
Jorg Tomeczkowski, Head Of Market Access, Janssen Cilag Germany
Mar 2016:25
Conference pass

HTA in Switzerland

PRICING AND MARKET ACCESS
  • Legal Context of HTA in Switzerland
  • HTA Processes
  • Implementation of HTA
Mar 2016:25
Conference pass

Landscape of Drug Pricing, Spending and Affordability In The U.S.

MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
Mar 2016:25
Conference pass

Speaking the Language of Patient Engagement

PATIENT AND PAYER ENGAGEMENT
Melissa Paige, Uva Cancer Center, Oncology Patient Access Principal Coordinator, Patient Advocate, U.V.A. Health System
Mar 2016:45
Conference pass
Mar 2016:45
Conference pass

Chair's closing remarks

PRICING AND MARKET ACCESS
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Mar 2016:45
Conference pass

Chair's closing remarks

RARE DISEASES
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Mar 2016:45
Conference pass

Chair's closing remarks

ADVANCED THERAPIES
Alexander Natz, Secretary General, EUCOPE
Mar 2016:45
Conference pass

Chair's closing remarks

PATIENT AND PAYER ENGAGEMENT
Anindita Sinha, Director, Global Market Access, Pfizer
Mar 2016:55
Conference pass

Chair's closing remarks

MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
last published: 18/Mar/19 14:45 GMT